Publications by authors named "O Garcea"
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
Front Immunol
September 2024
Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2.
Methods: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2 dose (Sputnik V or AZD1222) and 3 dose (homologous or heterologous schedule). Neutralizing capacity was against Omicron (BA.
Article Synopsis
- The study evaluated the effectiveness and safety of cladribine (CLAD) for treating relapsing-remitting multiple sclerosis in 240 patients across Argentina, focusing on clinical relapses and disease progression over 24 months.
- Results showed a significant decrease in annual relapse rates from 1.19 to 0.19, with many patients achieving no evidence of disease activity (NEDA) at both 12 months (84.2%) and 24 months (77%).
- The study also monitored lymphopenia, finding that grade 1 lymphopenia was the most common, while severe grade 4 lymphopenia was rare, suggesting CLAD is a safe treatment option.
Introduction: The primary objective of the core data set is to reduce heterogeneity and promote harmonization among data sources in EM, thereby reducing the time needed to execute real life data collection efforts. Recently, a group led by the Multiple Sclerosis Data Alliance has developed a core data set for collecting real-world data on multiple sclerosis (MS) globally. Our objective was to adapt this global data set to the needs of Latin America, so that it can be implemented by the registries already developed and in the process of development in the region.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the occurrence of SARS-CoV-2 breakthrough infections in vaccinated people with multiple sclerosis (PwMS) receiving high-efficacy disease-modifying therapies (HET) in Argentina.
- The analysis involved 228 adult PwMS who were fully vaccinated with vaccines like AstraZeneca and Sputnik, primarily receiving cladribine as their HET.
- The results indicated a breakthrough infection rate of 3.5 cases per 10,000 patients per day, with higher risks observed in patients treated with ocrelizumab compared to other therapies.
Article Synopsis
- Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are classified by their effectiveness, with high-efficacy treatments (HETs) having limited data in Latin America, particularly Argentina.
- A study using the RelevarEM registry found that 19% of 2,450 patients with relapsing-remitting MS (RRMS) were on HETs, with many switching due to treatment failures, leading to a significant increase in HET usage from 11.65% to 29.55% over two time periods.
- The research highlighted rapid growth in HET adoption, with the most common treatments being alemtuzumab and cladribine, and emphasized understanding the demographics